MLYS Stock Summary and Trading Ideas (Mineralys Therapeutics | NASDAQ:MLYS)

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Mineralys Therapeutics trades on the NASDAQ stock market under the symbol MLYS.

As of January 9, 2026, MLYS stock price climbed to $33.37 with 1,268,345 million shares trading.

MLYS has a beta of 0.90, meaning it tends to be less sensitive to market movements. MLYS has a correlation of 0.02 to the broad based SPY ETF.

MLYS has a market cap of $2.64 billion. This is considered a Mid Cap stock.

The top ETF exchange traded funds that MLYS belongs to (by Net Assets): XBI, VTI, IWM, VXF, IBB.

MLYS has outperformed the market in the last year with a return of +197.9%, while the SPY ETF gained +19.0%. However, in the most recent history, MLYS shares have underperformed the stock market with its stock returning -15.3% in the last 3 month period and -10.2% for the last 2 week period, while SPY has returned +3.7% and +0.5%, respectively.

MLYS support price is $32.07 and resistance is $34.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MLYS shares will trade within this expected range on the day.